ClinicalTrials.gg
Not yet recruitingNCT06456203ACERUpdated Jun 13, 2024

Trial of Artificial Intelligence for Chest Radiography

An interventional study of AI in Pneumonia and Lung Cancer, sponsored by Duke-NUS Graduate Medical School. Not yet recruiting. Open to participants aged 14 Years to 130 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by Duke-NUS Graduate Medical School · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10,000
Allocation
Randomized
Ages
14 Years to 130 Years
Sex
All
01

Study summary

Randomized Clinical Trial of the impact of Chest radiograph AI-assisted triage and report generation upon clinical outcomes and an economic analysis of impact of AI decision support on radiology service delivery.

Read the detailed description

Randomized, prospective selection of patients. Control group involves radiologists reporting chest radiographs as per reference standard clinical workflow Intervention group involves radiologists assisted with AI reporting an AI-triaged worklist of chest radiographs using an AI report generation tool Clinical outcomes on patients are studied at pre-determined study endpoints, including time to discharge from the hospital and re-admission rates.

Economic analysis on cost-avoidance from man-hours saved from report generation and triage.

02

Conditions studied

  • Pneumonia
  • Lung Cancer

Keywords

  • Radiology
  • artificial intelligence
  • triage
  • radiography
03

In context

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 128 across 978 interventional studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

Duke-NUS Graduate Medical School is the lead sponsor of 63 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients attending radiography to have chest radiographs during the study period

Exclusion criteria

Exclusion Criteria:

  • age below 14
  • deceased before discharge
  • chest radiograph performed in non-standard projections
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10,000 participants (estimated)

Study arms

  • No intervention
    Control Arm

    Chest radiographs reported with AI assistance

  • Active comparator
    AI assisted

    AI assisted detection, triage and reporting of CXR

    Diagnostic Test: AI

Interventions

  • Diagnostic testAI

    Artificial intelligence triage and reporting system

06

What researchers measure

Primary outcomes

  1. Report generation time

    Time for radiologist to produce each individual CXR report

    Time frame: 12 months

  2. Turnaround Time

    Time from patient arrival at radiography department to time for clinical team to receive report

    Time frame: 12 months

  3. Time to discharge

    Time from patient arrival at radiography department to time to discharge from hospital

    Time frame: 12 months

Secondary outcomes

  1. 30-day patient readmission rate

    Rate of readmission of patient to hospital after discharge within 30 days

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Sep 2025, 11 months later.

Of 260 non-industry interventional studies with no phase under Pneumonia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 11 months is below that.

Counting every sponsor, half of 267 studies reached it within 22 months; a quarter within 11 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2024
First posted
Jun 13, 2024
StartEst.
Oct 2024
Primary completionEst.
Sep 2025
CompletionEst.
Dec 2025
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06456203
Lead sponsor
Duke-NUS Graduate Medical School
Responsible party
Charlene Liew (Clinical Assistant Professor, Duke-NUS Graduate Medical School) — Principal investigator
First posted
Jun 13, 2024
Start date
Oct 2024 (estimated)
Primary completion
Sep 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jun 13, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion